Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2003-05-14
2009-11-10
Desai, Anand U (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C424S179100
Reexamination Certificate
active
07615543
ABSTRACT:
An agent for use in medicine, which agent comprises a plurality of ligands covalently co-linked so as to form a complex with a plurality of C-reactive protein (CRP) molecules in the presence thereof, wherein (i) at least two of the ligands are the same or different and are capable of being bound by ligand binding sites present on the CRP molecules; or (ii) at least one of the ligands is capable of being bound by a ligand binding site present on a CRP molecule, and at least one other of the ligands is capable of being bound by a ligand binding site present on a serum amyloid P component (SAP) molecule.
REFERENCES:
patent: 4640913 (1987-02-01), Wissner et al.
patent: 5064817 (1991-11-01), Yedgar et al.
patent: 5681829 (1997-10-01), Tempesta et al.
patent: 5811568 (1998-09-01), Bierer et al.
patent: 6764826 (2004-07-01), Yeh et al.
patent: 2003/0171251 (2003-09-01), Pepys
patent: 2001-302485 (2001-10-01), None
patent: 2001 302485 (2001-10-01), None
patent: WO 01/94951 (2001-12-01), None
patent: WO 03/013508 (2003-02-01), None
Bourla et al., “Age-related macular degeneration: a practical approach to a challenging disease”, J Am Geriatr Soc 54: 1130-1135 (2006).
Lu et al., “Synthetic Analogues of Irlbacholine: A Novel Antifungal Plant Metabolite Isolated form Irlbachia Alata”, J. Nat. Prod. 62: 824-828 (1999).
Pepys et al., Targeted pharamacological depletion of serum amyloid P component for treatment of human anyloidosis, Nature, 2002 Macmillan Magazines Ltd., pp. 254-259, (May 16, 2002).
Christner et al., Binding of Human Serum Amyloid P-Component to Phosphocholine, Archives of Biochemistry and Biophysics, Academic Press, Inc., vol. 314 ( No. 2), pp. 337-343, (Nov. 1, 1994).
Liuzzo et al., The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina, The New England Journal of Medicine, 1st ed., Massachusetts Medical Society, vol. 331 ( No. 7), pp. 417-424, 1994.
Hirschfield et al., Therapeutic inhibition of C-reactive protein—novel drugs, novel mechanisms, Medical Research Society, abstract, Feb. 5, 2003.
Baltz, M.L., de Beer, F.C., Feinstein, A., Munn, E.A., Milstein, C.P., Fletcher, T.C., March, J.F., Taylor, J., Bruton, C., Clamp, J.R., Davies, AJ.S. and Pepys, M.B. (1982) Phylogenetic aspects of C-reactive protein and related proteins:Ann. N. Y. Acad Sci., 389: 49-75.
Beranek, J.T. (1997) C-reactive protein and complement in myocardial infarction and postinfarction heart failure.Eur. Heart J., 18: 1834-1835.
Beranek, J.T. (1998) C-reactive protein in postinfarction heart rupture.Am. HeartJ., 136: 563-564.
Berman et al., (1986) Binding of C-Reactive Protein to Nucleated Cells Leads to Complement Activation without Cytolysis,J. Immunol., 136(4): 1354-1359.
Bhakdi et al., Possible Protective Role for C-Reactive Protein in Atherogenesis,Circulation, p. 1870-1876 (2001a).
Bhakdi et al., Beyond Cholesterol: the Enigma of Artherosclerosis Revisited,Thromb. Haemost., p. 639-645 (2004b).
Bhakdi, S., Dorweiler, B., Kirchmann, R., Torzewski, J., Weise, E., Tranum-Jensen, J., Walev, I. and Wieland, E. (1995) On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety.J. Exp. Med, 182: 1959-1971.
Bhakdi, S., Torzewski, M., Klouche, M. and Hemmes, M. (1999) Complement and atherogenesis. Binding of CRP to degraded, nonoxidized LDL enhances complement activation.Arterioscler. Thromb. Vasc. Biol., 19: 2348-2354.
Bickerstaff, M.C.M., Botto, M., Hutchinson, W.L., Herbert, J., Tennent, G.A., Bybee, A., Mitchell, D.A., Cook, H.T., Butler, P.J.G., Walport, M.J. and Pepys, M.B. (1999) Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity.Nature Med., 5: 694-697.
Boralessa, H., de Beer, F.C., Manchie, A. Whitwam, J.G. and Pepys, M.B. (1986) C-reactive protein in patients undergoing cardiac surgery.Anaesthesia, 41: 11-15.
Cermak, J., Key, N.S., Bach, R.R., Balla, J., Jacob, H.S. and Vercellotti, G.M. (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor.Blood, 82: 513-520.
Chang et al., (2002) C-Reactive Protein Binds to both Oxidized LDL and Apoptotic Cells Through Recognition of a Common Ligand: Phosphorylcholine of Oxidized Phospholipids,Proc. Natl. Acad. Sci. U.S.A., vol. 99 (No. 20) p. 13043-13048.
Claus, D.R., Siegel, J., Petras, K., Osmand, A.P. and Gewurz, H. (1977) Interactions of C-reactive protein with the first component of human complement.J. Immunol., 119: 187-192.
Culley, F.J., Bodman-Smith, K.B., Ferguson, M.A.J., Nikolaev, AN., Shantilal, N. and Raynes, J.G. (2000) C-reactive protein binds to phosphorylated carbohydrates.Glycobiology, 10: 59-65.
Danesh, J., Collins, R., Appleby, P. and Peto, R. (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease.J. Am. Coll. Cardiol., 279: 1477-1482.
Danesh, J., Whincup, P., Walker, M., Lennon, L., Thomson, A., Appleby, P., Gallimore, J.R. and Pepys, M.B. (2000) Low-grade inflammation and coronary heart disease: new prospective studies and updated meta-analyses.B.MJ, 321: 199-204.
de Beaufort, A.J., Langermans, J.A.M., Matze-van der Lans, A.M., Hiemstra, P.S., Vossen, J.M. and Van Furth, R. (1997) Difference in binding of killed and liveStreptococcus pneumoniaeserotypes by C-reactive protein.Scand. J. Immunol., 46: 597-600.
de Beer, F.C., Baltz, M.L., Munn, E.A., Feinstein, A., Taylor, J., Bruton, C., Clamp, J.R. and Pepys, M.B. (1982) Isolation and characterisation of C-reactive protein and serum amyloid P component in the rat.Immunology, 45: 55-70.
de Beer, F.C., Hind, C.R.K., Fox, K.M., Allan, R., Maseri, A. and Pepys, M.B. (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.Br. Heart J, 47: 239-243.
de Beer, F.C., Soutar, A.K., Baltz, M.L., Trayner, I., Feinstein, A. and Pepys, M.B. (1982) Low density and very low density lipoproteins are selectively bound by aggregated C-reactive protein. J.Exp. Med, 156: 230-242.
de Winter, R.J., Bholasingh, R., Lijmer, J.G., Koster, R.W., Gorgels, J.P.M.C., Schouten, Y., Hoek, F.J. and Sanders, G.T. (1999) Independent prognostic value of C-reactive protein and troponin I in patients with unstable angina or non-Q-wave myocardial infarction.Cardiovasc. Res., 42: 240-245.
Du Clos, T.W. (1989) C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J.Immunol., 143: 2553-2559.
Du Clos, T.W., Mold, C., Paterson, P.Y., Alroy, J. and Gewurz, H. (1981) Localization of C-reactive protein in inflammatory lesions of experimental allergic encephalomyelitis.Clin. Exp. lmmunol., 43: 565-573.
Finland, M. and Dowling, H.F. (1935) Cutaneous reactions and antibody response to intracutaneous injections of pneumococcus polysaccharides.J. ImmunoL, 29: 285-299.
Fletcher, T.C., White, A. and Baldo, B.A. (1980) Isolation of a phosphorylcholine-containing component from the turbot tapeworm,Bothriocephalus scorpii(Muller) and its reaction with C-reactive protein.Parasite Immunol., 2: 237-248.
Gershov, D., Kim, S., Brot, N. and Elkon, K.B. (2000) C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity.J. Exp. Med, 192: 1353-1363.
Gill et al., (2004) Human C-Reactive Protein Increases Cerebral Infarct Size After Middle Cerebral Artery Occlusion in Adult Rats,J. Cerebral Blood Flow&Metabolism, vol. 24 (No. 11), p. 1214-1218.
Gitlin, J.D., Gitlin, J.1. and Gitlin, D. (1977) Localisation of C-reactive protein in synovium of patients with rheumatoid arthritis.Arthritis Rheum., 20: 1491-1499.
Griselli, M., Herbert, J., Hutchinson, W.L., Taylor, K.M., Sohail, M., Krausz, T. and Pepys, M.B. (1999) C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J.Exp. Med., 190: 1733-1739.
Haverkate, F., Thompson, S.G., Pyke, S.D.M., Gallimore, J.R. and Pepys, M.B. (1997) Production of C-reactive protein and risk
Desai Anand U
Frommer & Lawrence & Haug LLP
Kowalski Thomas J.
Lu Deborah L.
Pentraxin Therapeutics Limited
LandOfFree
Treatment and prevention of tissue damage does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment and prevention of tissue damage, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment and prevention of tissue damage will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4143025